Global Onychomycosis Treatment Market
Global Onychomycosis Treatment Market

Onychomycosis Treatment Comprehensive Study by Application (Hospitals, Dermatology Clinics, Retail Pharmacies, Online Pharmacies), Treatment (Systemic Antifungal Agents, Lasers, Photodynamic Therapy, Others), Onychomycosis (Distal and Lateral Subungual Onychomycosis, Superficial White Onychomycosis, Proximal Subungual Onychomycosis, Candidal Onychomycosis), Age (Adults, Children) Players and Region - Global Market Outlook to 2026

Onychomycosis Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 217 Pages 173 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Onychomycosis Treatment Market?

Onychomycosis is the infection in nails due to the fungi like non-dermatophyte moulds, yeasts and dermatophytes. The onychomycosis is categorised as distal and lateral subungual onychomycosis, superficial white onychomycosis, proximal subungual onychomycosis, candidal onychomycosis. Onychomycosis treatment is required as it causes pain and further infection of the toenail and its treatment requires a longer time. It can be treated by systemic antifungal agents, lasers and photodynamic therapy. Systemic antifungal agents are increasingly used as it is most effective and has cure rates of 76% for terbinafine, 63% for itraconazole with pulse dosing, 59% for itraconazole with continuous dosage.

The market study is being classified, by Application (Hospitals, Dermatology Clinics, Retail Pharmacies and Online Pharmacies) and major geographies with country level break-up.

GlaxoSmithKline (United Kingdom), Pfizer Inc. (United States), Galderma S.A. (Switzerland), Reddy's Laboratories (UK) Ltd. (United Kingdom), Valeant Pharmaceuticals (Canada), Sanofi S.A. (France), Moberg Pharma (Sweden) and DermBiont, Inc (United States) are some of the key players profiled in the study.

Segment Analysis
Analyst at AMA have segmented the market study of Global Onychomycosis Treatment market by Type, Application and Region.

On the basis of geography, the market of Onychomycosis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Growing Prevalence of Nails Funga Infection in People
  • Need for the Treatment to Reduce the Pain and Further Infection Due to Fungi

Market Trend
  • Increased Consumption of Systemic Antifungals Agents Because if its Effective Treatment Result

Restraints
  • Side Effects Related Risks with the Onychomycosis Treatment

Opportunities
  • Surging Awwareess about the Infection-related Dangerous Diseases will Boost the Onychomycosis Treatment Market
  • Emerging Number of Advanced Treatment for Onychomycosis

Challenges
  • regulatory guideline son the Production of and Supplying of Onychomycosis Medication


Market Leaders and some development strategies
On 21st October 2020, DermBiont, Inc., a clinical-stage precision dermatology company targeting skin diseases at their root cause has expanded its pipeline and therapeutic modalities with the acquisition of SeylanMED, Inc. This strategic acquisition delivers multi-factorial value, and it expands the company's therapeutic pipeline with a first-in-class, targeted topical small molecule as well as our mission to address skin diseases at their root cause.
On 29th April 2020, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for JUBLIA (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range included in the product's label to children six years of age and older.1 JUBLIA was first approved in June 2014 in patients 18 years and older.


Key Target Audience
Onychomycosis Treatment Providers, Onychomycosis Treatment Industry Association, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Hospitals
  • Dermatology Clinics
  • Retail Pharmacies
  • Online Pharmacies
By Treatment
  • Systemic Antifungal Agents
  • Lasers
  • Photodynamic Therapy
  • Others

By Onychomycosis
  • Distal and Lateral Subungual Onychomycosis
  • Superficial White Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis

By Age
  • Adults
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Prevalence of Nails Funga Infection in People
      • 3.2.2. Need for the Treatment to Reduce the Pain and Further Infection Due to Fungi
    • 3.3. Market Challenges
      • 3.3.1. Regulatory guideline son the Production of and Supplying of Onychomycosis Medication
    • 3.4. Market Trends
      • 3.4.1. Increased Consumption of Systemic Antifungals Agents Because if its Effective Treatment Result
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Onychomycosis Treatment, by Application, Treatment, Onychomycosis, Age and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Onychomycosis Treatment (Value)
      • 5.2.1. Global Onychomycosis Treatment by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Dermatology Clinics
        • 5.2.1.3. Retail Pharmacies
        • 5.2.1.4. Online Pharmacies
      • 5.2.2. Global Onychomycosis Treatment by: Treatment (Value)
        • 5.2.2.1. Systemic Antifungal Agents
        • 5.2.2.2. Lasers
        • 5.2.2.3. Photodynamic Therapy
        • 5.2.2.4. Others
      • 5.2.3. Global Onychomycosis Treatment by: Onychomycosis (Value)
        • 5.2.3.1. Distal and Lateral Subungual Onychomycosis
        • 5.2.3.2. Superficial White Onychomycosis
        • 5.2.3.3. Proximal Subungual Onychomycosis
        • 5.2.3.4. Candidal Onychomycosis
      • 5.2.4. Global Onychomycosis Treatment by: Age (Value)
        • 5.2.4.1. Adults
        • 5.2.4.2. Children
      • 5.2.5. Global Onychomycosis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Onychomycosis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Galderma S.A. (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Reddy's Laboratories (UK) Ltd. (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Valeant Pharmaceuticals (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi S.A. (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Moberg Pharma (Sweden)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. DermBiont, Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Onychomycosis Treatment Sale, by Application, Treatment, Onychomycosis, Age and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Onychomycosis Treatment (Value)
      • 7.2.1. Global Onychomycosis Treatment by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Dermatology Clinics
        • 7.2.1.3. Retail Pharmacies
        • 7.2.1.4. Online Pharmacies
      • 7.2.2. Global Onychomycosis Treatment by: Treatment (Value)
        • 7.2.2.1. Systemic Antifungal Agents
        • 7.2.2.2. Lasers
        • 7.2.2.3. Photodynamic Therapy
        • 7.2.2.4. Others
      • 7.2.3. Global Onychomycosis Treatment by: Onychomycosis (Value)
        • 7.2.3.1. Distal and Lateral Subungual Onychomycosis
        • 7.2.3.2. Superficial White Onychomycosis
        • 7.2.3.3. Proximal Subungual Onychomycosis
        • 7.2.3.4. Candidal Onychomycosis
      • 7.2.4. Global Onychomycosis Treatment by: Age (Value)
        • 7.2.4.1. Adults
        • 7.2.4.2. Children
      • 7.2.5. Global Onychomycosis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Onychomycosis Treatment: by Application(USD Million)
  • Table 2. Onychomycosis Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 3. Onychomycosis Treatment Dermatology Clinics , by Region USD Million (2015-2020)
  • Table 4. Onychomycosis Treatment Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 5. Onychomycosis Treatment Online Pharmacies , by Region USD Million (2015-2020)
  • Table 6. Onychomycosis Treatment: by Treatment(USD Million)
  • Table 7. Onychomycosis Treatment Systemic Antifungal Agents , by Region USD Million (2015-2020)
  • Table 8. Onychomycosis Treatment Lasers , by Region USD Million (2015-2020)
  • Table 9. Onychomycosis Treatment Photodynamic Therapy , by Region USD Million (2015-2020)
  • Table 10. Onychomycosis Treatment Others , by Region USD Million (2015-2020)
  • Table 11. Onychomycosis Treatment: by Onychomycosis(USD Million)
  • Table 12. Onychomycosis Treatment Distal and Lateral Subungual Onychomycosis , by Region USD Million (2015-2020)
  • Table 13. Onychomycosis Treatment Superficial White Onychomycosis , by Region USD Million (2015-2020)
  • Table 14. Onychomycosis Treatment Proximal Subungual Onychomycosis , by Region USD Million (2015-2020)
  • Table 15. Onychomycosis Treatment Candidal Onychomycosis , by Region USD Million (2015-2020)
  • Table 16. Onychomycosis Treatment: by Age(USD Million)
  • Table 17. Onychomycosis Treatment Adults , by Region USD Million (2015-2020)
  • Table 18. Onychomycosis Treatment Children , by Region USD Million (2015-2020)
  • Table 19. South America Onychomycosis Treatment, by Country USD Million (2015-2020)
  • Table 20. South America Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 21. South America Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 22. South America Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 23. South America Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 24. Brazil Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 25. Brazil Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 26. Brazil Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 27. Brazil Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 28. Argentina Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 29. Argentina Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 30. Argentina Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 31. Argentina Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 32. Rest of South America Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 34. Rest of South America Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 35. Rest of South America Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 36. Asia Pacific Onychomycosis Treatment, by Country USD Million (2015-2020)
  • Table 37. Asia Pacific Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 39. Asia Pacific Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 40. Asia Pacific Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 41. China Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 42. China Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 43. China Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 44. China Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 45. Japan Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 46. Japan Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 47. Japan Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 48. Japan Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 49. India Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 50. India Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 51. India Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 52. India Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 53. South Korea Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 54. South Korea Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 55. South Korea Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 56. South Korea Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 57. Taiwan Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 58. Taiwan Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 59. Taiwan Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 60. Taiwan Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 61. Australia Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 62. Australia Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 63. Australia Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 64. Australia Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 69. Europe Onychomycosis Treatment, by Country USD Million (2015-2020)
  • Table 70. Europe Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 71. Europe Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 72. Europe Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 73. Europe Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 74. Germany Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 75. Germany Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 76. Germany Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 77. Germany Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 78. France Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 79. France Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 80. France Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 81. France Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 82. Italy Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 83. Italy Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 84. Italy Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 85. Italy Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 86. United Kingdom Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 87. United Kingdom Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 88. United Kingdom Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 89. United Kingdom Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 90. Netherlands Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 91. Netherlands Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 92. Netherlands Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 93. Netherlands Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 94. Rest of Europe Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 95. Rest of Europe Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 96. Rest of Europe Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 97. Rest of Europe Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 98. MEA Onychomycosis Treatment, by Country USD Million (2015-2020)
  • Table 99. MEA Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 100. MEA Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 101. MEA Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 102. MEA Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 103. Middle East Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 104. Middle East Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 105. Middle East Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 106. Middle East Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 107. Africa Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 108. Africa Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 109. Africa Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 110. Africa Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 111. North America Onychomycosis Treatment, by Country USD Million (2015-2020)
  • Table 112. North America Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 113. North America Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 114. North America Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 115. North America Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 116. United States Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 117. United States Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 118. United States Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 119. United States Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 120. Canada Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 121. Canada Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 122. Canada Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 123. Canada Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 124. Mexico Onychomycosis Treatment, by Application USD Million (2015-2020)
  • Table 125. Mexico Onychomycosis Treatment, by Treatment USD Million (2015-2020)
  • Table 126. Mexico Onychomycosis Treatment, by Onychomycosis USD Million (2015-2020)
  • Table 127. Mexico Onychomycosis Treatment, by Age USD Million (2015-2020)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Onychomycosis Treatment: by Application(USD Million)
  • Table 137. Onychomycosis Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 138. Onychomycosis Treatment Dermatology Clinics , by Region USD Million (2021-2026)
  • Table 139. Onychomycosis Treatment Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 140. Onychomycosis Treatment Online Pharmacies , by Region USD Million (2021-2026)
  • Table 141. Onychomycosis Treatment: by Treatment(USD Million)
  • Table 142. Onychomycosis Treatment Systemic Antifungal Agents , by Region USD Million (2021-2026)
  • Table 143. Onychomycosis Treatment Lasers , by Region USD Million (2021-2026)
  • Table 144. Onychomycosis Treatment Photodynamic Therapy , by Region USD Million (2021-2026)
  • Table 145. Onychomycosis Treatment Others , by Region USD Million (2021-2026)
  • Table 146. Onychomycosis Treatment: by Onychomycosis(USD Million)
  • Table 147. Onychomycosis Treatment Distal and Lateral Subungual Onychomycosis , by Region USD Million (2021-2026)
  • Table 148. Onychomycosis Treatment Superficial White Onychomycosis , by Region USD Million (2021-2026)
  • Table 149. Onychomycosis Treatment Proximal Subungual Onychomycosis , by Region USD Million (2021-2026)
  • Table 150. Onychomycosis Treatment Candidal Onychomycosis , by Region USD Million (2021-2026)
  • Table 151. Onychomycosis Treatment: by Age(USD Million)
  • Table 152. Onychomycosis Treatment Adults , by Region USD Million (2021-2026)
  • Table 153. Onychomycosis Treatment Children , by Region USD Million (2021-2026)
  • Table 154. South America Onychomycosis Treatment, by Country USD Million (2021-2026)
  • Table 155. South America Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 156. South America Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 157. South America Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 158. South America Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 159. Brazil Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 160. Brazil Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 161. Brazil Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 162. Brazil Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 163. Argentina Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 164. Argentina Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 165. Argentina Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 166. Argentina Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 167. Rest of South America Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 168. Rest of South America Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 169. Rest of South America Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 170. Rest of South America Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 171. Asia Pacific Onychomycosis Treatment, by Country USD Million (2021-2026)
  • Table 172. Asia Pacific Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 173. Asia Pacific Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 174. Asia Pacific Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 175. Asia Pacific Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 176. China Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 177. China Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 178. China Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 179. China Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 180. Japan Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 181. Japan Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 182. Japan Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 183. Japan Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 184. India Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 185. India Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 186. India Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 187. India Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 188. South Korea Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 189. South Korea Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 190. South Korea Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 191. South Korea Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 192. Taiwan Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 193. Taiwan Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 194. Taiwan Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 195. Taiwan Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 196. Australia Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 197. Australia Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 198. Australia Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 199. Australia Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 204. Europe Onychomycosis Treatment, by Country USD Million (2021-2026)
  • Table 205. Europe Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 206. Europe Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 207. Europe Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 208. Europe Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 209. Germany Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 210. Germany Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 211. Germany Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 212. Germany Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 213. France Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 214. France Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 215. France Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 216. France Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 217. Italy Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 218. Italy Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 219. Italy Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 220. Italy Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 221. United Kingdom Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 222. United Kingdom Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 223. United Kingdom Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 224. United Kingdom Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 225. Netherlands Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 226. Netherlands Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 227. Netherlands Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 228. Netherlands Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 229. Rest of Europe Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 230. Rest of Europe Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 231. Rest of Europe Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 232. Rest of Europe Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 233. MEA Onychomycosis Treatment, by Country USD Million (2021-2026)
  • Table 234. MEA Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 235. MEA Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 236. MEA Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 237. MEA Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 238. Middle East Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 239. Middle East Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 240. Middle East Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 241. Middle East Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 242. Africa Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 243. Africa Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 244. Africa Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 245. Africa Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 246. North America Onychomycosis Treatment, by Country USD Million (2021-2026)
  • Table 247. North America Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 248. North America Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 249. North America Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 250. North America Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 251. United States Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 252. United States Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 253. United States Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 254. United States Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 255. Canada Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 256. Canada Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 257. Canada Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 258. Canada Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 259. Mexico Onychomycosis Treatment, by Application USD Million (2021-2026)
  • Table 260. Mexico Onychomycosis Treatment, by Treatment USD Million (2021-2026)
  • Table 261. Mexico Onychomycosis Treatment, by Onychomycosis USD Million (2021-2026)
  • Table 262. Mexico Onychomycosis Treatment, by Age USD Million (2021-2026)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Onychomycosis Treatment: by Application USD Million (2015-2020)
  • Figure 5. Global Onychomycosis Treatment: by Treatment USD Million (2015-2020)
  • Figure 6. Global Onychomycosis Treatment: by Onychomycosis USD Million (2015-2020)
  • Figure 7. Global Onychomycosis Treatment: by Age USD Million (2015-2020)
  • Figure 8. South America Onychomycosis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Onychomycosis Treatment Share (%), by Country
  • Figure 10. Europe Onychomycosis Treatment Share (%), by Country
  • Figure 11. MEA Onychomycosis Treatment Share (%), by Country
  • Figure 12. North America Onychomycosis Treatment Share (%), by Country
  • Figure 13. Global Onychomycosis Treatment share by Players 2020 (%)
  • Figure 14. Global Onychomycosis Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Onychomycosis Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Galderma S.A. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Galderma S.A. (Switzerland) Revenue: by Geography 2020
  • Figure 23. Reddy's Laboratories (UK) Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 24. Reddy's Laboratories (UK) Ltd. (United Kingdom) Revenue: by Geography 2020
  • Figure 25. Valeant Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 26. Valeant Pharmaceuticals (Canada) Revenue: by Geography 2020
  • Figure 27. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 29. Moberg Pharma (Sweden) Revenue, Net Income and Gross profit
  • Figure 30. Moberg Pharma (Sweden) Revenue: by Geography 2020
  • Figure 31. DermBiont, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 32. DermBiont, Inc (United States) Revenue: by Geography 2020
  • Figure 33. Global Onychomycosis Treatment: by Application USD Million (2021-2026)
  • Figure 34. Global Onychomycosis Treatment: by Treatment USD Million (2021-2026)
  • Figure 35. Global Onychomycosis Treatment: by Onychomycosis USD Million (2021-2026)
  • Figure 36. Global Onychomycosis Treatment: by Age USD Million (2021-2026)
  • Figure 37. South America Onychomycosis Treatment Share (%), by Country
  • Figure 38. Asia Pacific Onychomycosis Treatment Share (%), by Country
  • Figure 39. Europe Onychomycosis Treatment Share (%), by Country
  • Figure 40. MEA Onychomycosis Treatment Share (%), by Country
  • Figure 41. North America Onychomycosis Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline (United Kingdom)
  • Pfizer Inc. (United States)
  • Galderma S.A. (Switzerland)
  • Reddy's Laboratories (UK) Ltd. (United Kingdom)
  • Valeant Pharmaceuticals (Canada)
  • Sanofi S.A. (France)
  • Moberg Pharma (Sweden)
  • DermBiont, Inc (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation